Infinity Pharmaceuticals, Inc. (INFI)
Stock Price Chart
Key Info
| Market Cap | 68.88M |
| Revenue (ttm) | 1.44M |
| Net Income (ttm) | -43.16M |
| Shares Out | 58.87M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 11, 2020 |
| Last Price | $1.17 |
| Previous Close | $1.07 |
| Change ($) | 0.10 |
| Change (%) | 9.35% |
| Day's Open | 1.20 |
| Day's Range | 1.15 - 1.24 |
| Day's Volume | 4,182,716 |
| 52-Week Range | 0.60 - 1.68 |
More Stats
| Market Cap | 68.88M |
| Enterprise Value | 27.52M |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 58.87M |
| Float | 39.35M |
| EPS (basic) | -0.75 |
| EPS (diluted) | -0.75 |
| FCF / Share | -0.70 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 46,726 |
| Short Ratio | 0.05 |
| Short % of Float | 0.17% |
| Beta | 1.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 47.90 |
| PB Ratio | 8.03 |
| Revenue | 1.44M |
| Operating Income | -41.55M |
| Net Income | -43.16M |
| Free Cash Flow | -40.19M |
| Net Cash | 41.36M |
| Net Cash / Share | 0.70 |
| Gross Margin | -2,181.85% |
| Operating Margin | -2,889.71% |
| Profit Margin | -2,999.20% |
| FCF Margin | -2,794.65% |
| ROA | -44.36% |
| ROE | -474.68% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.05 | 22.15 | 6.00 | 18.72 | 109 | 165 | - | 47.11 | 92.77 | 71.33 |
| Revenue Growth | -86.23% | 269.1% | -67.95% | -82.83% | -33.9% | - | - | -49.22% | 30.06% | - |
| Gross Profit | 3.05 | 22.15 | 6.00 | 18.72 | 109 | 165 | - | 47.11 | 92.77 | 71.33 |
| Operating Income | -45.66 | -11.93 | -36.45 | -30.89 | -127 | -7.92 | -128 | -52.81 | -38.53 | -48.97 |
| Net Income | -47.06 | -11.25 | -41.83 | -30.10 | -128 | -17.42 | -127 | -53.96 | -40.04 | -48.98 |
| Shares Outstanding | 56.98 | 55.41 | 50.56 | 49.61 | 49.08 | 48.56 | 47.94 | 31.71 | 26.62 | 26.32 |
| Earnings Per Share | -0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 |
| Operating Cash Flow | -41.53 | -4.71 | -36.71 | -154 | -83.65 | 118 | -114 | -80.14 | -33.11 | -26.59 |
| Capital Expenditures | -2.33 | - | 0.71 | 1.48 | -6.43 | -1.36 | -1.75 | -1.30 | -1.54 | -1.95 |
| Free Cash Flow | -43.86 | -4.71 | -36.00 | -153 | -90.08 | 116 | -116 | -81.44 | -34.65 | -28.53 |
| Cash & Equivalents | 42.76 | 58.59 | 57.61 | 93.22 | 245 | 334 | 215 | 327 | 116 | 101 |
| Total Debt | 1.93 | - | 6.00 | 19.59 | 20.01 | - | - | - | 37.55 | - |
| Net Cash / Debt | 40.83 | 58.59 | 51.61 | 73.63 | 225 | 334 | 215 | 327 | 78.85 | 101 |
| Assets | 49.01 | 60.22 | 59.35 | 126 | 289 | 369 | 231 | 336 | 124 | 125 |
| Liabilities | 41.29 | 7.76 | 11.62 | 43.20 | 190 | 160 | 29.44 | 25.46 | 109 | 75.08 |
| Book Value | 7.73 | 52.46 | 47.73 | 82.45 | 98.56 | 209 | 201 | 310 | 15.43 | 49.48 |
Company Profile
Company Details
| Full Name | Infinity Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 25 |
| CEO | Adelene Q. Perkins |
Stock Information
| Ticker Symbol | INFI |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: INFI |
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.